Javier Garzón is leader of Neuropharmacology at the Cajal Institute. He has a 40-year-long research experience as a neuropharmacologist at the University of California, San Francisco (UCSF, USA), Max Plank Institute (Germany) and Agencia Estatal CSIC (Spain). His research interests include behavioral and molecular neuropharmacology, behavioral and therapeutic effects of opioid receptors and sigma receptor ligands in normal and pathological models (neurologic and mental diseases). Dr Garzón's team made major discoveries in the field of GPCR signaling, a field where he is regarded as an expert. During his career, J. Garzón has established active collaborations with many academic groups and Pharma company researchers. He has published 140+ research articles in relevant journals.
Javier Garzón is leader of Neuropharmacology at the Cajal Institute. He has a 40-year-long research experience as a neuropharmacologist at the University of California, San Francisco (UCSF, USA), Max Plank Institute (Germany) and Agencia Estatal CSIC (Spain). His research interests include behavioral and molecular neuropharmacology, behavioral and therapeutic effects of opioid receptors and sigma receptor ligands in normal and pathological models (neurologic and mental diseases). Dr Garzón's team made major discoveries in the field of GPCR signaling, a field where he is regarded as an expert. During his career, J. Garzón has established active collaborations with many academic groups and Pharma company researchers. He has published 140+ research articles in relevant journals.